- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.03. | Better Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 14.03. | Better Therapeutics terminates staff as it seeks alternative options | 7 | MassDevice | ||
| 14.03. | Digital diabetes app maker Better Therapeutics shutters operations, lays off staff | 1 | FierceBiotech | ||
| 14.03. | Better Therapeutics tumbles 81% on plans to wind down operations | 4 | Reuters | ||
| 14.03. | Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq | 40 | Business Wire | SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX) (the "Company") announced today that the Company is terminating its employees and will explore strategic alternatives, including... ► Artikel lesen | |
| 11.03. | Better Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.03. | Better Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.03. | Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 369 | ACCESSWIRE | ORLANDO, FL / ACCESSWIRE / March 1, 2024 / RedChip Companies will air interviews with Better Therapeutics, Inc. (Nasdaq:BTTX) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money... ► Artikel lesen | |
| 22.02. | Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status | 1 | Zacks | ||
| 20.02. | Better Therapeutics wins FDA breakthrough nod for liver disease-treating digital therapeutic | 2 | MassDevice | ||
| 06.02. | Better Therapeutics secures rebate deal for diabetes app | - | Investing.com | ||
| 06.02. | Better Therapeutics, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 08.01. | Better Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.01. | Better Therapeutics, Glooko partner on digital diabetes management | 2 | MassDevice | ||
| 03.01. | Better Therapeutics adds digital treatment into Glooko's diabetes management platform | 1 | FierceBiotech | ||
| 02.01. | Better Therapeutics applies for FDA breakthrough designation for NASH device | 1 | Seeking Alpha | ||
| 27.12.23 | Better Therapeutics, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 16.12.23 | Better Therapeutics, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 13.12.23 | Better Therapeutics files to sell 20M shares of common stock for holders | 1 | Seeking Alpha | ||
| 13.12.23 | Better Therapeutics, Inc. - S-1, General form for registration of securities | 1 | SEC Filings |
Seite:
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,595 | -2,45 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,465 | +1,09 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase... ► Artikel lesen | |
| TREVENA | 0,360 | +4,20 % | Trevena, Inc.: Trevena Awarded OLINVYK Agreement with Premier, Inc. | CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,930 | -1,48 % | KI im Gesundheitswesen mit evotec, Defence Therapeutics, Bayer: Revolutionäre Fortschritte und medizinische Durchbrüche | Im Gesundheitswesen nimmt Künstliche Intelligenz (KI) immer mehr an Fahrt auf. KI-basierte Systeme können medizinische Datenbanken nutzen, um in der Forschung kostbare Zeit zu sparen, die es Unternehmen... ► Artikel lesen | |
| IBIO | 1,770 | 0,00 % | iBio files to sell 10.57M shares of common stock for holders | ||
| GINKGO BIOWORKS | 0,925 | 0,00 % | Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products | IGDI will leverage Ginkgo's Adaptive Laboratory Evolution technology to improve its sourdough starter culture product PADUA, Italy and BOSTON, April 16, 2024 /PRNewswire/ -- Il Granaio delle Idee... ► Artikel lesen | |
| T2 BIOSYSTEMS | 3,320 | -100,00 % | T2 Biosystems, Inc. - 8-K, Current Report | ||
| TRAWS PHARMA | 0,630 | -3,82 % | Rigosertib sodium by Traws Pharma for Epidermolysis Bullosa: Likelihood of Approval | ||
| OCULAR THERAPEUTIX | 5,650 | +2,69 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic Retinopathy | 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm No patients in the AXPAXLI... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,310 | 0,00 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,980 | +0,51 % | Oncolytics Biotech Inc.: Oncolytics Biotech Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA | Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancer
Overall survival results from the randomized HR+/HER2- metastatic... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,400 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer | Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of DirectorsSALT LAKE... ► Artikel lesen | |
| UNITY BIOTECHNOLOGY | 1,434 | +1,41 % | UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | SOUTH SAN FRANCISCO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 26,310 | 0,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,754 | 0,00 % | Assertio Holdings, Inc.: Assertio Reports Fourth Quarter and Full Year 2023 Financial Results | Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million 2024 Full Year Outlook for Net Product Sales of $110 to $125 Million, Adjusted EBITDA of... ► Artikel lesen |
BETTER THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,045 Euro und damit +27,43 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
